Global Real-World Evidence Solution Market to reach USD 5,240.07 million at a CAGR of 8.07% by 2032, Evaluates DelveInsight

According to DelveInsight's analysis, The growth of the real-world evidence (RWE) solutions market is mainly fueled by the rising prevalence of chronic diseases and their significant influence on healthcare outcomes. Moreover, advancements in big data analytics, machine learning, and artificial intelligence are enabling more efficient processing and interpretation of extensive real-world datasets. Additionally, the expanding use of RWE solutions within the pharmaceutical and biotechnology industries-to improve drug development, facilitate regulatory approvals, ensure market access, and monitor post-market safety and effectiveness-is further driving market expansion.

DelveInsight's "Real-World Evidence Solution Market Insights, Competitive Landscape and Market Forecast-2032" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Real-World Evidence Solution companies actively working in the market.

To know more about why North America is leading the market growth in the Real-World Evidence Solution market, get a snapshot of the report Real-World Evidence Solution Market Trends
https://www.delveinsight.com/sample-request/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Real-World Evidence Solution Overview
Real-World Evidence (RWE) Solutions are tools and methodologies used to collect, analyze, and interpret data from real-world sources-outside of traditional clinical trials-to understand how medical treatments perform in routine clinical practice. These sources include electronic health records (EHRs), insurance claims, patient registries, wearable devices, and patient-reported outcomes. RWE solutions help healthcare stakeholders-such as pharmaceutical companies, clinicians, and regulators-assess treatment effectiveness, safety, and patient outcomes, support regulatory decisions, guide drug development, and inform value-based care strategies. They bridge the gap between controlled clinical trial results and real-world patient experiences.

DelveInsight Analysis: The global real-world evidence solutions market size was valued at approximately USD 2,832.33 million in 2024 and is projected to grow at a CAGR of 8.07% from 2025 to 2032, reaching around USD 5,240.07 million by 2032.

Real-World Evidence Solution Market Insights
Geographically, North America is projected to hold the largest share of the global real-world evidence solutions market in 2024 among all regions. This dominance is driven by the rise in clinical trials prompted by the growing burden of chronic diseases, along with rapid technological advancements such as artificial intelligence, machine learning, and advanced data analytics, which enhance data processing and interpretation for improved insights into treatment outcomes. Additionally, the strong presence of major pharmaceutical and biotechnology companies, coupled with continuous R&D efforts in drug discovery and development, further supports the expansion of the real-world evidence solutions market across North America.

To read more about the latest highlights related to Real-World Evidence Solution, get a snapshot of the key highlights entailed in the Real-World Evidence Solution Market Insights
https://www.delveinsight.com/report-store/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Real-World Evidence Solution Market Report
• In April 2024, Flatiron Health, a healthtech company focused on improving cancer care with real-world data, renewed its collaboration with the National Comprehensive Cancer Network® (NCCN®). This partnership, which began in 2014, involves maintaining the NCCN Quality & Outcomes Database, a cloud-based repository of data from NCCN member institutions.
• In September 2023, Accentre helped Mount Sinai Health System migrate its Epic EMR system to the Microsoft Azure cloud, marking the largest instance of Epic on Azure. In collaboration with Avanade and Microsoft, Mount Sinai began this transformation in the year 2022 to innovate and improve healthcare.
• In August 2023, Thermo Fisher Scientific Inc. announced that it had completed the acquisition of CorEvitas, LLC, a top provider of regulatory-grade real-world evidence for medical treatments, from Audax Private Equity for $912.5 million in cash. The agreement was initially announced in July 2023.
• Thus, owing to such developments in the market, rapid growth will be observed in the Real-World Evidence Solution market during the forecast period

Key Players in the Real-World Evidence Solution Market
Some of the key market players operating in the Real-World Evidence Solution market include- IQVIA Inc., Optum, Inc., Flatiron Health, Oracle, Parexel International (MA) Corporation, Aetion, Inc., Tempus, Syapse, Inc., IBM, PerkinElmer Inc., Syneos Health, TriNetX, Evidera, Clinerion, Cegedim Health Data, and others.

Which MedTech key players in the Real-World Evidence Solution market are set to emerge as the trendsetter explore @ Key Real-World Evidence Solution Companies
https://www.delveinsight.com/sample-request/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Real-World Evidence Solution Market Landscape
Furthermore, the pharmaceutical and biotechnology sectors are increasingly acknowledging the importance of real-world evidence (RWE) in supporting drug development, regulatory approvals, and market access strategies. Traditional randomized clinical trials (RCTs) are often costly, time-intensive, and limited in patient diversity, prompting companies to leverage RWE for identifying target populations, refining study criteria, and optimizing trial design. This approach accelerates recruitment, reduces expenses, and enhances trial success rates, encouraging greater investment in RWE solutions. For example, in August 2021, real-world evidence played a key role in securing approval for a new indication of Jardiance (empagliflozin), demonstrating its cardiovascular benefits in heart failure patients, including those without diabetes, complementing findings from the EMPEROR-Reduced Phase III trial. By offering valuable insights into treatment performance in real-world settings, RWE enhances therapy effectiveness, safety, and overall healthcare innovation.
However, challenges related to data validation, operational complexities, and cybersecurity concerns may pose minor restraints to the growth of the global real-world evidence solutions market.

Scope of the Real-World Evidence Solution Market Report
• Coverage: Global
• Study Period: 2022-2032
• Real-World Evidence Solution Market Segmentation By Data Source: Medical Claims, Clinical Data, Pharmacy Data, and Other Data
• Real-World Evidence Solution Market Segmentation By Therapeutic Areas: Oncology, Immunology, Neurology, Cardiovascular, and Others
• Real-World Evidence Solution Market Segmentation By End-User: Pharmaceuticals & Medical Device Companies, Healthcare Providers, and Others
• Real-World Evidence Solution Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World
• Key Real-World Evidence Solution Companies: IQVIA Inc., Optum, Inc., Flatiron Health, Oracle, Parexel International (MA) Corporation, Aetion, Inc., Tempus, Syapse, Inc., IBM, PerkinElmer Inc., Syneos Health, TriNetX, Evidera, Clinerion, Cegedim Health Data, and others
• Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View

Interested in knowing how the Real-World Evidence Solution market will grow by 2032? Click to get a snapshot of the Real-World Evidence Solution Market Analysis
https://www.delveinsight.com/sample-request/real-world-evidence-solution-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Contact Us
Gaurav Bora
info@delveinsight.com
+14699457679
www.delveinsight.com

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.